TipRanks on MSN

Vertex Pharmaceuticals price target lowered to $438 from $439 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $438 from $439 and keeps an Equal Weight rating on the shares.

Vertex’s quest for a breakthrough in Type 1 diabetes

Vertex Pharmaceuticals’ CRISPR-based therapy made history as the first drug of its type, transforming care options for sickle ...
StockStory.org on MSN

Vertex Pharmaceuticals (VRTX): Buy, Sell, or Hold Post Q2 Earnings?

Over the past six months, Vertex Pharmaceuticals’s stock price fell to $413.23. Shareholders have lost 12.5% of their capital ...

What Does the Market Think About Vertex Pharmaceuticals Inc?

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...
IEEE

Efficient and Robust Graph Coloring Algorithm for Graph Coloring Problem: Malatya Vertex Coloring Algorithm

Abstract: The graph coloring problem involves coloring the nodes of a graph using the minimum number of colors such that no two adjacent nodes share the same color. This NP-hard problem has various ...
IEEE

Privacy-Preserving Multi-Label Propagation Based on Federated Learning

Abstract: Multi-label propagation algorithms (MLPAs) aim to find vertex communities in a complex network or a cloud system by propagating and updating vertex labels, which have been widely applied in ...

Vertex Pharmaceuticals: Trikafta And Alyftrek Cement Market Leadership

Vertex's revenue was $2.96 billion in the second quarter of 2025, beating the consensus forecast by $58 million. Click here to find out why VRTX is a Buy.